Oncology Learning Network

Updated safety results from the phase 3 #MANEUVER trial demonstrate that #pimicotinib was associated with manageable and largely reversible adverse events among patients with symptomatic, unresectable #TGCT. Learn more: hubs.ly/Q047Mc2b0

Tian Zhang, MD, discusses optimal front-line #immunotherapy strategies for patients with metastatic renal cell #carcinoma. Learn more: hubs.ly/Q047JDS50

Based on results from the #SWOG1826 trial, the FDA has approved #nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma. Learn more: hubs.ly/Q047KVSC0

Estelamari Rodriguez, MD, discusses the importance of continuing #immunotherapy after surgery to maintain immune activation and reduce recurrence risk in patients with early-stage resectable #NSCLC. Learn more: hubs.ly/Q047xHrT0

Dory Abelman, PhD, HBHSc, presents a blood-based cell-free #DNA approach that accurately detects minimal residual disease and predicts relapse in #MM up to 1 year earlier than clinical progression. Learn more: hubs.ly/Q047xmnf0

Ranee Mehra, MD discusses results from cohort 2 of the phase 1b/2 #OrigAMI4 study, which evaluated first-line subcutaneous #amivantamab plus #pembrolizumab in #HPV-negative, PD-L1–positive head and neck squamous cell carcinoma. Learn more: hubs.ly/Q047kyqD0

In a real-world ES-SCLC cohort treated with #atezolizumab plus #chemotherapy, long-term survival was achieved in a subset of patients, with former smoking status and performance status predicting durable response. Learn more: hubs.ly/Q047k9Rm0

Thomas Roberts, MD, MBA, shared study results which analyzed a tumor-informed ctDNA-based MRD assay in primarily #HPV-independent, locally advanced #HNSCC. Learn more: hubs.ly/Q0477gWW0

The FDA granted traditional approval to frontline #encorafenib in combination with #cetuximab and #fluorouracil-based chemotherapy for patients with #mCRC harboring a BRAF V600E mutation, as detected by an FDA-authorized test. Learn more: hubs.ly/Q04776_d0

Results from the #SWOG S162 study demonstrated that Tokyo-172 #BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer. Learn more: hubs.ly/Q045W8LQ0

Long-term follow-up results from the phase 3 CheckMate 649 trial demonstrate that adding #nivolumab to chemotherapy prolongs survival in previously untreated non-HER2-positive, unresectable or metastatic gastroesophageal #adenocarcinoma. Learn more: hubs.ly/Q045Vyk-0

Ira Zackon, MD, shared results from a large real-world analysis which found #venetoclax plus a hypomethylating agent is a feasible and effective therapeutic option for patients with #AML aged 70 years and older. Learn more: hubs.ly/Q045Vxzh0

In patients with extensive-stage small cell lung cancer, concurrent #radiotherapy during #tarlatamab treatment was associated with low rates of severe toxicity and local tumor regression. Learn more: hubs.ly/Q045VkbN0

We are proud to announce the launch of the new Radiopharmaceutical Education Institute (RPEI), a clinician-focused platform dedicated to advancing the clinical integration of radiopharmaceutical therapies in oncology. Learn More: hmpgloballearningnetwork.com/site/rpei/news…

#Auceliciclib was well-tolerated and demonstrated preliminary disease control with promising safety among heavily pretreated patients with advanced solid tumors and recurrent high-grade #glioma. Learn more: hubs.ly/Q045VwKC0

Among patients with #myelofibrosis undergoing allogeneic transplantation, improved outcomes and long-term survival remain limited by high non-relapse mortality. Learn more: hubs.ly/Q045Vv_B0

Campbell Roxburgh, MD, discusses findings from a serial sampling study evaluating immune effects of neoadjuvant #radiotherapy regimens in patients with locally advanced rectal cancer. Learn more: hubs.ly/Q045Vq390

Richard Finn, MD, discusses post hoc analysis results from the #REFINE study assessing #regorafenib in patients with unresectable hepatocellular carcinoma. Learn more: hubs.ly/Q045VhBp0

Sara Tolaney, MD, discusses results from the phase 3 #ASCENT-04 trial, assessing #sacituzumab govitecan plus pembrolizumab in PD-L1–positive, locally advanced unresectable or metastatic triple-negative breast cancer. Learn more: hubs.ly/Q045SZ4G0

Results from a phase 2 trial show that #tinengotinib demonstrates strong antitumor activity in patients with advanced #cholangiocarcinoma who developed resistance to prior FGFR inhibitor therapy. Learn more: hubs.ly/Q045SRKs0